Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models   new Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources

GENE - CHEMICAL INTERACTIONS REPORT

RGD ID: 1306992
Species: Rattus norvegicus
RGD Object: Gene
Symbol: Ercc1
Name: ERCC excision repair 1, endonuclease non-catalytic subunit
Acc ID: CHEBI:27899
Term: cisplatin
Definition: A diamminedichloroplatinum compound in which the two ammine ligands and two chloro ligands are oriented in a cis planar configuration around the central platinum ion. An anticancer drug that interacts with, and forms cross-links between, DNA and proteins, it is used as a neoplasm inhibitor to treat solid tumours, primarily of the testis and ovary. Commonly but incorrectly described as an alkylating agent due to its mechanism of action (but it lacks alkyl groups).
Chemical ID: MESH:D002945
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction is comprised of a complex set of reactions and/or regulatory events, possibly involving additional chemicals and/or gene products.
Object SymbolQualifierEvidenceWithReferenceSourceNotesOriginal Reference(s)
Ercc1increases expressionEXP 6480464CTDCisplatin results in increased expression of ERCC1 mRNAPMID:26739623
Ercc1multiple interactionsEXP 6480464CTDLovastatin promotes the reaction [Cisplatin results in increased expression of ERCC1 mRNA]PMID:26739623
Ercc1affects expressionISOERCC1 (Homo sapiens)6480464CTDCisplatin affects the expression of ERCC1 mRNA; Cisplatin affects the expression of ERCC1 proteinPMID:21750216 PMID:24799992
Ercc1decreases response to substanceISOERCC1 (Homo sapiens)6480464CTDERCC1 protein results in decreased susceptibility to Cisplatin; ERCC1 results in decreased susceptibility to CisplatinPMID:21093896 PMID:21315089 PMID:21621119 PMID:33164868
Ercc1decreases response to substanceISOErcc1 (Mus musculus)6480464CTDERCC1 results in decreased susceptibility to CisplatinPMID:21722328
Ercc1increases expressionISOERCC1 (Homo sapiens)6480464CTDCisplatin results in increased expression of ERCC1 mRNA; Cisplatin results in increased expression of ERCC1 proteinPMID:21165580 PMID:21315089 PMID:21996734
Ercc1increases response to substanceISOERCC1 (Homo sapiens)6480464CTDERCC1 protein results in increased susceptibility to CisplatinPMID:21076943
Ercc1multiple interactionsISOERCC1 (Homo sapiens)6480464CTD[Cisplatin co-treated with Fluorouracil] results in decreased expression of ERCC1 mRNA; [Cisplatin results in decreased susceptibility to Cisplatin] which results in increased expression of ERCC1 mRNA; [Curcumin results in decreased expression of ERCC1 protein] which results in increased susceptibility to Cisplatin; [ERCC1 protein binds to ERCC4 protein] which results in decreased susceptibility to Cisplatin; [sclareol co-treated with Cisplatin] results in decreased expression of ERCC1 protein; [sodium arsenite co-treated with Cisplatin] results in increased expression of ERCC1 protein; DUSP6 inhibits the reaction [Cisplatin results in increased expression of ERCC1 mRNA]; ERCC1 gene polymorphism affects the susceptibility to [Cisplatin co-treated with S 1 (combination)]; ERCC1 gene polymorphism affects the susceptibility to [Gefitinib co-treated with Cisplatin]; ERCC1 gene SNP results in increased susceptibility to [Cisplatin co-treated with Fluorouracil]; ERCC1 mRNA affects the susceptibility to [Cisplatin co-treated with Fluorouracil]; ERCC1 mutant form inhibits the reaction [RRM2 mutant form promotes the reaction [TP53 mutant form promotes the reaction [Cisplatin results in increased phosphorylation of H2AX protein]]]; ERCC1 mutant form inhibits the reaction [TP53 mutant form promotes the reaction [Cisplatin results in increased phosphorylation of H2AX protein]]; ERCC1 mutant form promotes the reaction [RRM2 mutant form promotes the reaction [TP53 mutant form results in increased susceptibility to Cisplatin]]; mirdametinib inhibits the reaction [Cisplatin results in increased expression of ERCC1 mRNA]; mirdametinib inhibits the reaction [Cisplatin results in increased expression of ERCC1 protein]PMID:15173087 PMID:15737843 PMID:21264830 PMID:21286668 PMID:21357694 PMID:21364592 PMID:21493726 PMID:21696631 PMID:21875941 PMID:21996734 PMID:30871063 PMID:33164868
Go Back to source page   Continue to Ontology report